Press "Enter" to skip to content

Share Market Live: Sensex, Nifty Open Higher; Natco Pharma Jumps To A Record High – BloombergQuint

Shares of the drugmaker jumped as much as 20% to a record high of Rs 1188.95 after it initiated phase-III clinical trials of Molnupiravir capsules to evaluate its efficacy in treating patients with mild Covid-19.

The Hyderabad-based firm said the first dose under the phase-III trials was given to a patient in the city-based Yashoda Hospitals. The clinical trial is planned in 32 hospitals across the country.

Pre-clinical data has shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication, the drug firm noted.

Patients treated with Molnupiravir achieved response within five days of therapy, indicating that the duration of treatment with the drug is short, with the additional advantage of it being an oral therapy, it added.